Related Experiment Video
Updated: Mar 27, 2026
08:18
Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
Published on: July 27, 2022
1.7K
Design and Development of Prolong-acting Intelligent Nano-depot (PaIND) for Improving Patient Adherence
Hardik Rana1, Shreya Gohel2, Prachi Rabari2
1Department of Pharmaceutics, Anand Pharmacy College, Anand, 388001, Gujarat, India. hardikrana1439@gmail.com.
AAPS Pharmscitech
|March 26, 2026
Summary
Researchers developed a novel Prolong-acting intelligent nano-depot (PaIND) for hypercholesterolemia patients using Rosuvastatin (RSV). This innovative formulation significantly reduces the need for frequent medication, improving patient adherence and treatment outcomes.
Area of Science:
- Pharmaceutical Sciences
- Biomaterials Science
- Drug Delivery Systems
Background:
- Medication non-adherence is a significant challenge in managing chronic conditions like hypercholesterolemia.
- Current treatment regimens often require frequent dosing, leading to poor patient compliance.
- There is a need for advanced drug delivery systems that offer prolonged drug release and improve adherence.
Purpose of the Study:
- To develop a Prolong-acting intelligent nano-depot (PaIND) for Rosuvastatin (RSV) delivery.
- To enhance medication adherence in hypercholesterolemia patients by reducing dosing frequency.
- To create a patient-friendly, stable, and sterile nano-depot system.
Main Methods:
- Formulation of PaIND using poly(lactic-co-glycolic acid 75:25) (PLGA), Dimethyl sulfoxide (DMSO), sesame oil, Span 80, and Tween 80.
- Application of Quality by Design (QbD) principles, including risk assessment and Taguchi design for screening critical material attributes (CMAs) and process parameters (CPPs).
- Optimization using Central Composite Design (CCD) to achieve desired drug release profiles, particle size, and gelling time.
Main Results:
- The optimized PaIND demonstrated sustained Rosuvastatin (RSV) release of 86.99% over 30 days without burst release.
- Characterization revealed nano-sized particles (173 nm), appropriate gelling time (3.6 s), low polydispersity index (PDI), and negative zeta potential.
- The formulation exhibited high entrapment efficiency, improved stability, sterility, and good transmittance, indicating suitability for prolonged drug delivery.
Conclusions:
- The developed PaIND system successfully integrates regulatory compliance requirements for advanced drug delivery.
- The nano-depot formulation offers a promising, patient-friendly approach for managing hypercholesterolemia with prolonged Rosuvastatin release.
- The PaIND system is ready for preclinical trials, paving the way for potential commercialization.
Related Concept Videos
01:26Oral Drug Delivery Systems: Continuous-Release Systems
205
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
205
01:23Modified-Release Drug Delivery Systems: Classification
249
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
249
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
85
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
85
01:11Oral Drug Delivery Systems: Delayed-Release Systems
134
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
134
01:19Modified-Release Drug Delivery Systems: Overview
149
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
149
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
308
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
308